Vertiv Holdings Co vs GeneDx Holdings Corp — how do they compare? Vertiv Holdings Co trades at $305.31 (market cap $112.03B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Vertiv Holdings Co is far larger — about 62.2× GeneDx Holdings Corp's market cap, and Vertiv Holdings Co pays a 0.09% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| VRT | WGS | |
|---|---|---|
Market Cap | $112.03B | $1.80B |
Sector | Technology | Technology |
52-Week High | $376.23 | $167.51 |
52-Week Low | $121.82 | $34.51 |
Enterprise Value | $112.80B | $1.80B |
Dividend Yield | 0.09% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Trailing returns across standard periods
Latest headlines on both assets
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →